Literature DB >> 8154419

Effects of aminophylline on cardiac function and regional myocardial perfusion: implications regarding its antiischemic action.

F Crea1, A Gaspardone, L Araujo, R Da Silva, J C Kaski, G Davies, A Maseri.   

Abstract

Aminophylline improves exercise capacity in patients with angina. Because this drug does not dilate epicardial coronary vessels, its beneficial effect is from either a reduction of myocardial oxygen consumption or an improvement of myocardial blood flow distribution. This study was performed to assess the effects of aminophylline on cardiac function and on regional myocardial perfusion to establish the mechanisms of its antiischemic action. In 10 patients during cardiac catheterization hemodynamic parameters and cardiac volumes were obtained during baseline and after intravenous infusion of aminophylline. Aminophylline decreased left ventricular end-diastolic pressure (from 11 +/- 4 to 4 +/- 2 mmHg, p < 0.001), mean right atrial pressure (from 5 +/- 2 to 2 +/- 1 mmHg, p < 0.01), and left ventricular end-diastolic volume (from 117 +/- 36 to 88 +/- 36 ml, p < 0.01); it increased peak dp/dt (from 1931 +/- 329 to 2430 +/- 540 mmHg/sec, p < 0.001) and heart rate (from 69 +/- 9 to 76 +/- 14 beats/min, p < 0.05) and did not modify systolic aortic pressure (138 +/- 14 vs 137 +/- 16 mmHg, p = not significant [NS]). Estimated oxygen consumption during aminophylline (6.7 +/- 1.3 ml/min/gm) was similar to that during baseline (6.7 +/- 1.4 ml/min/gm). In another study in nine anesthetized dogs with a critical stenosis of the left anterior descending artery, myocardial perfusion was assessed by microspheres during control atrial pacing and during atrial pacing after aminophylline; left atrial pressure was kept constant throughout the study.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8154419     DOI: 10.1016/0002-8703(94)90548-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.

Authors:  Hsiao D Lieu; John C Shryock; Gregory O von Mering; Toufigh Gordi; Brent Blackburn; Ann W Olmsted; Luiz Belardinelli; Richard A Kerensky
Journal:  J Nucl Cardiol       Date:  2007-07       Impact factor: 5.952

Review 2.  Shedding Light on Treatment Options for Coronary Vasomotor Disorders: A Systematic Review.

Authors:  Federico Marchini; Graziella Pompei; Emanuele D'Aniello; Andrea Marrone; Serena Caglioni; Simone Biscaglia; Gianluca Campo; Matteo Tebaldi
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-09       Impact factor: 3.727

Review 3.  Coronary microvascular dysfunction: an update.

Authors:  Filippo Crea; Paolo G Camici; Cathleen Noel Bairey Merz
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

4.  A Double-Blinded, Randomized, Placebo-Controlled Clinical Trial of Aminophylline to Prevent Acute Kidney Injury in Children Following Congenital Heart Surgery With Cardiopulmonary Bypass.

Authors:  David M Axelrod; Scott M Sutherland; Andrew Anglemyer; Paul C Grimm; Stephen J Roth
Journal:  Pediatr Crit Care Med       Date:  2016-02       Impact factor: 3.624

Review 5.  Treatment of coronary microvascular dysfunction.

Authors:  C Noel Bairey Merz; Carl J Pepine; Hiroki Shimokawa; Colin Berry
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 13.081

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.